VNDA

Over the past six months, Vanda Pharmaceuticals' stock price has seen a significant increase. The FDA approval of NEREUS for motion sickness led to a surge in VNDA shares, and the FDA approved BYSANTI in February 2026. Vanda reported Q4 2025 earnings, which were followed by a decline in share price. The FDA accepted Vanda's Biologics License Application (BLA) for Imsidolimab in Generalized Pustular Psoriasis. Vanda reported Q1 2026 financial results, with total net product sales increasing year-over-year, and raised its full-year 2026 revenue guidance, but VNDA shares declined the day after. Vanda announced the U.S. commercial availability of NEREUS through a direct-to-consumer platform.